Akorn (AKRX) Receiving Somewhat Positive Media Coverage, Study Shows
Media stories about Akorn (NASDAQ:AKRX) have trended somewhat positive on Friday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Akorn earned a news impact score of 0.16 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.7657970273412 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
- Exclusive – Prosecutors identify Insys founder as unindicted co-conspirator in opioid case (uk.reuters.com)
- Akorn, Inc. (AKRX) Sees Significant Increase in Short Interest (americanbankingnews.com)
- Akorn, Inc. (AKRX) moves -2.26% away from 52-Week High = Technical Facts – Voice Of Analysts (analystsbuzz.com)
- Stock to Hold: Akorn, Inc. (AKRX) – Street Observer (press release) (streetobserver.com)
A number of analysts have commented on AKRX shares. Royal Bank Of Canada set a $34.00 price objective on shares of Akorn and gave the company a “hold” rating in a report on Saturday, May 27th. BidaskClub raised shares of Akorn from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Jefferies Group LLC reaffirmed a “hold” rating and set a $34.00 price objective on shares of Akorn in a research report on Wednesday, July 19th. TheStreet cut shares of Akorn from a “b-” rating to a “c” rating in a research report on Tuesday, August 1st. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and set a $34.00 price objective on shares of Akorn in a research report on Thursday, August 10th. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $28.56.
Akorn (NASDAQ:AKRX) opened at 32.99 on Friday. The stock has a 50 day moving average of $33.05 and a 200-day moving average of $31.08. The firm has a market cap of $4.12 billion, a price-to-earnings ratio of 33.32 and a beta of 1.38. Akorn has a 52-week low of $17.61 and a 52-week high of $34.00.
In other Akorn news, Director Brian Tambi sold 5,165 shares of the company’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $33.37, for a total transaction of $172,356.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Bruce Kutinsky sold 40,000 shares of the company’s stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $33.46, for a total transaction of $1,338,400.00. Following the sale, the chief operating officer now directly owns 317,480 shares of the company’s stock, valued at $10,622,880.80. The disclosure for this sale can be found here. 28.20% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This news story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/09/15/akorn-akrx-receiving-somewhat-positive-media-coverage-study-shows.html.
Akorn Company Profile
Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.
Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with MarketBeat.com's FREE daily email newsletter.